Apretude, Descovy, Truvada, and a generic version of Truvada—often referred to as PrEP—are approved for men at high risk of acquiring HIV. By Lisa L. Gill Updated by Justin Krajeski About ...
Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP).
The Scottish Medicines Consortium has approved the use of Gilead’s Truvada for use in preventing new HIV infections, so called pre-exposure prophylaxis (PrEP). The decision has been hailed as a ...
After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a pair of HIV prevention pills.
Two oral PrEP medications have been approved by the U.S. Food and Drug Administration (FDA)—Truvada and Descovy—and one injection drug called Apretude that must be taken once every two months.
To learn more about using Descovy or Truvada to treat your condition, talk with your doctor. You can also see this Descovy for PrEP article. Descovy and Truvada are used to treat HIV in children.
Truvada for PrEP, the name-brand version of the pill form of HIV prevention medication, was approved by the Food and Drug Administration in July 2012 for sexually active adults after having been ...
Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.
The federal government said Gilead failed to compensate the CDC for discovering that Truvada can prevent HIV ... drug's HIV-prevention regimen, known as PrEP, or pre-exposure prophylaxis, ignored ...
When taken regularly, pre-exposure prophylaxis medications like Truvada and Descovy offer significant protection to uninfected people. According to the CDC, PrEP can reduce the risk of sexual ...
In a Phase III trial in cisgender women, the twice-yearly injectable PrEP boasted 100% efficacy ... Lenacapavir proved to be 89% more effective than Truvada, and it reduced HIV infections by ...